GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gene Biotherapeutics Inc (OTCPK:CRXM) » Definitions » 10-Year ROIIC %

Gene Biotherapeutics (Gene Biotherapeutics) 10-Year ROIIC % : 0.00% (As of Dec. 2020)


View and export this data going back to . Start your Free Trial

What is Gene Biotherapeutics 10-Year ROIIC %?

10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year. Gene Biotherapeutics's 10-Year ROIIC % for the quarter that ended in Dec. 2020 was 0.00%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

The industry rank for Gene Biotherapeutics's 10-Year ROIIC % or its related term are showing as below:

CRXM's 10-Year ROIIC % is not ranked *
in the Biotechnology industry.
Industry Median: -33.26
* Ranked among companies with meaningful 10-Year ROIIC % only.

Gene Biotherapeutics 10-Year ROIIC % Historical Data

The historical data trend for Gene Biotherapeutics's 10-Year ROIIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gene Biotherapeutics 10-Year ROIIC % Chart

Gene Biotherapeutics Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
10-Year ROIIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Gene Biotherapeutics Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Dec17 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20
10-Year ROIIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Gene Biotherapeutics's 10-Year ROIIC %

For the Biotechnology subindustry, Gene Biotherapeutics's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gene Biotherapeutics's 10-Year ROIIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gene Biotherapeutics's 10-Year ROIIC % distribution charts can be found below:

* The bar in red indicates where Gene Biotherapeutics's 10-Year ROIIC % falls into.



Gene Biotherapeutics 10-Year ROIIC % Calculation

Gene Biotherapeutics's 10-Year ROIIC % for the quarter that ended in Dec. 2020 is calculated as:

10-Year ROIIC %=10-Year Incremental Net Operating Profit After Taxes (NOPAT)**/10-Year Incremental Invested Capital**
=( -1.262 (Dec. 2020) - -6.77 (Dec. 2010) )/( 1.308 (Dec. 2020) - 2.173 (Dec. 2010) )
=5.508/-0.865
=-636.76%***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Gene Biotherapeutics  (OTCPK:CRXM) 10-Year ROIIC % Explanation

Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.

High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.

Be Aware

It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.


Gene Biotherapeutics 10-Year ROIIC % Related Terms

Thank you for viewing the detailed overview of Gene Biotherapeutics's 10-Year ROIIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Gene Biotherapeutics (Gene Biotherapeutics) Business Description

Traded in Other Exchanges
N/A
Address
11230 Sorrento Valley Road, Suite 220, San Diego, CA, USA, 92121
Gene Biotherapeutics Inc is a clinical stage biotechnology company focused on pre-clinical, clinical, and commercialization of angiogenic gene therapy biotherapeutics for strategic niche markets primarily for the treatment of cardiovascular disease. The company's lead product candidate Generx is an angiogenic gene therapy product candidate designed for medical revascularization for the potential treatment of patients with myocardial ischemia and refractory angina due to advanced coronary artery disease.
Executives
Andrew M Leitch director 6615 CALLE PONTE BELLA, RANCHO SANTA FE CA 92091
Murray H Hutchison director C/O CADIZ INC., 550 SOUTH HOPE STREET, 2850, LOS ANGELES CA 90071
Dennis Mulroy officer: Chief Financial Officer
Ronald I Simon other: Former Director 485 MADISON AVENUE, 14TH FLOOR, NEW YORK NY 10022
Robert N Weingarten director, officer: PRESIDENT and CFO 5439 LOCKHURST DRIVE, WOODLAND HILLS CA 91367

Gene Biotherapeutics (Gene Biotherapeutics) Headlines